Therapeutic Monoclonal Antibodies (MABs) are a class of biologic drugs designed to target specific molecules in the body, primarily for treating diseases like cancer, autoimmune disorders, and infectious diseases. These drugs are engineered to bind to specific proteins or antigens on the surface of cells, disrupting disease progression or enhancing the immune response. Monoclonal antibodies are derived from a single clone of cells, which allows for the creation of drugs that are highly specific to the targeted antigen.
In the context of oncology, monoclonal antibodies are used to treat various cancers by either marking cancer cells for destruction by the immune system or directly interfering with the mechanisms that allow cancer cells to proliferate. These therapies have revolutionized the treatment of diseases like lymphoma, breast cancer, and colorectal cancer, offering targeted treatment with fewer side effects compared to traditional chemotherapy.
Market Size
The global Therapeutic Monoclonal Antibodies Drug market was valued at USD 162.41 billion in 2024 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2032, reaching an estimated USD 374.27 billion by the end of the forecast period.
This market growth is fueled by increasing cancer incidences, advancements in biologic drugs, and the growing demand for targeted therapies that offer better outcomes and fewer side effects.
North America is currently the largest market for therapeutic monoclonal antibodies, with a market size of USD 50.68 billion in 2024. This region is expected to continue its dominance, driven by high healthcare spending, advanced healthcare infrastructure, and an increasing number of clinical trials for monoclonal antibody therapies. Furthermore, Europe and Asia-Pacific are witnessing rapid market growth due to rising cancer rates and improving healthcare access.
Market Dynamics (Drivers, Restraints, Opportunities, and Challenges)
Drivers
-
Rising Cancer Incidences: Cancer remains one of the leading causes of death worldwide, and the increasing global incidence rates drive the demand for effective therapeutic options like monoclonal antibodies.
-
Technological Advancements: The development of next-generation monoclonal antibodies with improved efficacy and fewer side effects is propelling market growth.
-
Increased Investment in Biopharmaceutical R&D: Pharmaceutical companies are significantly investing in the R&D of monoclonal antibodies, leading to breakthroughs in their application for other diseases, including autoimmune disorders and chronic diseases.
Restraints
-
High Treatment Costs: The cost of monoclonal antibody therapies is significantly higher compared to traditional treatments, making it unaffordable for a large portion of the global population, particularly in emerging economies.
-
Regulatory Challenges: The approval process for monoclonal antibodies can be lengthy and expensive, leading to delays in the introduction of new therapies to the market.
-
Complex Manufacturing Process: The production of monoclonal antibodies is a complex process, requiring advanced technologies and facilities, which limits the ability of smaller players to enter the market.
Opportunities
-
Emerging Markets: The growing healthcare infrastructure in emerging markets, particularly in Asia and Latin America, presents opportunities for the expansion of monoclonal antibody treatments.
-
Combination Therapies: The increasing trend of combining monoclonal antibodies with other treatment modalities, such as chemotherapy and immunotherapy, is opening new avenues for treatment.
-
Orphan Drugs: The rise in rare disease diagnoses provides opportunities for monoclonal antibodies to serve as orphan drugs, treating diseases that currently have limited treatment options.
Challenges
-
Immune Response: Some patients develop resistance or immune reactions to monoclonal antibodies, which can limit their long-term effectiveness.
-
Global Access: While monoclonal antibodies are widely used in developed countries, access remains limited in low-income countries, affecting the overall market penetration.
-
Market Competition: The increasing number of monoclonal antibody drugs coming to market leads to heightened competition, forcing companies to constantly innovate to maintain their market position.
Regional Analysis
North America
North America dominates the Therapeutic Monoclonal Antibodies Drug market, with the U.S. holding the largest share due to its advanced healthcare system and high demand for cutting-edge treatments. The region is also a hub for biopharmaceutical R&D, with numerous clinical trials and FDA approvals for new monoclonal antibody drugs.
Europe
Europe is the second-largest market for therapeutic monoclonal antibodies. The demand for targeted therapies is high, particularly in Western Europe, with countries like Germany, the UK, and France leading in market adoption. The presence of major pharmaceutical companies and favorable regulatory environments further support the growth of the market in this region.
Asia-Pacific
The Asia-Pacific market is experiencing rapid growth, driven by the increasing prevalence of cancer and chronic diseases. The expanding middle class and improving healthcare infrastructure in countries like China and India are expected to drive further market growth in the region.
Latin America
Latin America, while a smaller market, is seeing an increasing adoption of monoclonal antibody therapies, especially in Brazil and Mexico, where healthcare access and infrastructure are improving.
Middle East & Africa
In the Middle East and Africa, there is a growing demand for monoclonal antibodies, particularly in wealthier nations like Saudi Arabia and the UAE. However, challenges such as high treatment costs and limited access to healthcare in some regions hinder overall market growth.
Competitor Analysis
Several key companies are leading the global Therapeutic Monoclonal Antibodies Drug market, including:
-
AbbVie
-
Johnson & Johnson
-
Novartis
-
Gilead Sciences
-
Roche
-
Bristol-Myers Squibb
-
Amgen
-
AstraZeneca
-
Merck & Co
-
Takeda
These companies dominate the market by leveraging their strong R&D capabilities, extensive portfolios of monoclonal antibodies, and established relationships with healthcare providers. Their competitive strategies include mergers and acquisitions, collaborations with research institutions, and the development of new drug formulations.
Global Therapeutic Monoclonal Antibodies Drug: Market Segmentation Analysis
This report provides a deep insight into the global Therapeutic Monoclonal Antibodies Drug market, covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trends, niche markets, key market drivers, and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Therapeutic Monoclonal Antibodies Drug Market. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Therapeutic Monoclonal Antibodies Drug market in any manner.
Market Segmentation (by Application)
-
Immune Diseases
-
Cancer
-
Other
Market Segmentation (by Type)
-
Mouse-derived Antibodies
-
Chimeric Antibodies
-
Humanized Antibodies
Key Company
-
AbbVie
-
Johnson & Johnson
-
Novartis
-
Gilead Sciences
-
Roche
-
Bristol-Myers Squibb
-
Amgen
-
AstraZeneca
-
Merck & Co
-
Takeda
-
Merck KGaA
-
Seagen
-
Eli Lilly
-
Ono Pharmaceutical
-
Pfizer
-
Regeneron
-
Innovent
-
Hengrui Medicine
Geographic Segmentation
-
North America (USA, Canada, Mexico)
-
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
-
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
-
South America (Brazil, Argentina, Columbia, Rest of South America)
-
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
FAQ
What is the current market size of the Therapeutic Monoclonal Antibodies Drug market?
- The global market size was estimated at USD 162.41 billion in 2024 and is expected to reach USD 415.45 billion by 2032.
Which are the key companies operating in the Therapeutic Monoclonal Antibodies Drug market?
- Key players include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, and several others.
What are the key growth drivers in the Therapeutic Monoclonal Antibodies Drug market?
- Growth drivers include rising cancer incidences, technological advancements, and increased investments in biopharmaceutical R&D.
Which regions dominate the Therapeutic Monoclonal Antibodies Drug market?
- North America currently dominates the market, followed by Europe and the rapidly growing Asia-Pacific region.
What are the emerging trends in the Therapeutic Monoclonal Antibodies Drug market?
- Emerging trends include the combination of monoclonal antibodies with other therapies, expansion into emerging markets, and advances in manufacturing technologies.
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Therapeutic Monoclonal Antibodies Drug Market
- Overview of the regional outlook of the Therapeutic Monoclonal Antibodies Drug Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Therapeutic Monoclonal Antibodies Drug
1.2 Key Market Segments
1.2.1 Therapeutic Monoclonal Antibodies Drug Segment by Type
1.2.2 Therapeutic Monoclonal Antibodies Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Therapeutic Monoclonal Antibodies Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Therapeutic Monoclonal Antibodies Drug Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Therapeutic Monoclonal Antibodies Drug Market Competitive Landscape
3.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Manufacturers (2019-2025)
3.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Manufacturers (2019-2025)
3.3 Therapeutic Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Therapeutic Monoclonal Antibodies Drug Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Therapeutic Monoclonal Antibodies Drug Sales Sites, Area Served, Product Type
3.6 Therapeutic Monoclonal Antibodies Drug Market Competitive Situation and Trends
3.6.1 Therapeutic Monoclonal Antibodies Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Therapeutic Monoclonal Antibodies Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Therapeutic Monoclonal Antibodies Drug Industry Chain Analysis
4.1 Therapeutic Monoclonal Antibodies Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Therapeutic Monoclonal Antibodies Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Therapeutic Monoclonal Antibodies Drug Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2019-2025)
6.3 Global Therapeutic Monoclonal Antibodies Drug Market Size Market Share by Type (2019-2025)
6.4 Global Therapeutic Monoclonal Antibodies Drug Price by Type (2019-2025)
7 Therapeutic Monoclonal Antibodies Drug Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Therapeutic Monoclonal Antibodies Drug Market Sales by Application (2019-2025)
7.3 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) by Application (2019-2025)
7.4 Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2025)
8 Therapeutic Monoclonal Antibodies Drug Market Consumption by Region
8.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region
8.1.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region
8.1.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Therapeutic Monoclonal Antibodies Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Therapeutic Monoclonal Antibodies Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Therapeutic Monoclonal Antibodies Drug Market Production by Region
9.1 Global Production of Therapeutic Monoclonal Antibodies Drug by Region (2019-2025)
9.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2019-2025)
9.3 Global Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Therapeutic Monoclonal Antibodies Drug Production
9.4.1 North America Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2025)
9.4.2 North America Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Therapeutic Monoclonal Antibodies Drug Production
9.5.1 Europe Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2025)
9.5.2 Europe Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Therapeutic Monoclonal Antibodies Drug Production (2019-2025)
9.6.1 Japan Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2025)
9.6.2 Japan Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Therapeutic Monoclonal Antibodies Drug Production (2019-2025)
9.7.1 China Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2025)
9.7.2 China Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 AbbVie
10.1.1 AbbVie Therapeutic Monoclonal Antibodies Drug Basic Information
10.1.2 AbbVie Therapeutic Monoclonal Antibodies Drug Product Overview
10.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.1.4 AbbVie Business Overview
10.1.5 AbbVie Therapeutic Monoclonal Antibodies Drug SWOT Analysis
10.1.6 AbbVie Recent Developments
10.2 Johnson and Johnson
10.2.1 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Basic Information
10.2.2 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Overview
10.2.3 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.2.4 Johnson and Johnson Business Overview
10.2.5 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug SWOT Analysis
10.2.6 Johnson and Johnson Recent Developments
10.3 Novartis
10.3.1 Novartis Therapeutic Monoclonal Antibodies Drug Basic Information
10.3.2 Novartis Therapeutic Monoclonal Antibodies Drug Product Overview
10.3.3 Novartis Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.3.4 Novartis Therapeutic Monoclonal Antibodies Drug SWOT Analysis
10.3.5 Novartis Business Overview
10.3.6 Novartis Recent Developments
10.4 Gilead Sciences
10.4.1 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Basic Information
10.4.2 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Overview
10.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.4.4 Gilead Sciences Business Overview
10.4.5 Gilead Sciences Recent Developments
10.5 Roche
10.5.1 Roche Therapeutic Monoclonal Antibodies Drug Basic Information
10.5.2 Roche Therapeutic Monoclonal Antibodies Drug Product Overview
10.5.3 Roche Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.5.4 Roche Business Overview
10.5.5 Roche Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Basic Information
10.6.2 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Overview
10.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Amgen
10.7.1 Amgen Therapeutic Monoclonal Antibodies Drug Basic Information
10.7.2 Amgen Therapeutic Monoclonal Antibodies Drug Product Overview
10.7.3 Amgen Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.7.4 Amgen Business Overview
10.7.5 Amgen Recent Developments
10.8 AstraZeneca
10.8.1 AstraZeneca Therapeutic Monoclonal Antibodies Drug Basic Information
10.8.2 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Overview
10.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.8.4 AstraZeneca Business Overview
10.8.5 AstraZeneca Recent Developments
10.9 Merck and Co
10.9.1 Merck and Co Therapeutic Monoclonal Antibodies Drug Basic Information
10.9.2 Merck and Co Therapeutic Monoclonal Antibodies Drug Product Overview
10.9.3 Merck and Co Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.9.4 Merck and Co Business Overview
10.9.5 Merck and Co Recent Developments
10.10 Takeda
10.10.1 Takeda Therapeutic Monoclonal Antibodies Drug Basic Information
10.10.2 Takeda Therapeutic Monoclonal Antibodies Drug Product Overview
10.10.3 Takeda Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.10.4 Takeda Business Overview
10.10.5 Takeda Recent Developments
10.11 Merck KGaA
10.11.1 Merck KGaA Therapeutic Monoclonal Antibodies Drug Basic Information
10.11.2 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Overview
10.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.11.4 Merck KGaA Business Overview
10.11.5 Merck KGaA Recent Developments
10.12 Seagen
10.12.1 Seagen Therapeutic Monoclonal Antibodies Drug Basic Information
10.12.2 Seagen Therapeutic Monoclonal Antibodies Drug Product Overview
10.12.3 Seagen Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.12.4 Seagen Business Overview
10.12.5 Seagen Recent Developments
10.13 Eli Lilly
10.13.1 Eli Lilly Therapeutic Monoclonal Antibodies Drug Basic Information
10.13.2 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Overview
10.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.13.4 Eli Lilly Business Overview
10.13.5 Eli Lilly Recent Developments
10.14 Ono Pharmaceutical
10.14.1 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Basic Information
10.14.2 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Overview
10.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.14.4 Ono Pharmaceutical Business Overview
10.14.5 Ono Pharmaceutical Recent Developments
10.15 Pfizer
10.15.1 Pfizer Therapeutic Monoclonal Antibodies Drug Basic Information
10.15.2 Pfizer Therapeutic Monoclonal Antibodies Drug Product Overview
10.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.15.4 Pfizer Business Overview
10.15.5 Pfizer Recent Developments
10.16 Regeneron
10.16.1 Regeneron Therapeutic Monoclonal Antibodies Drug Basic Information
10.16.2 Regeneron Therapeutic Monoclonal Antibodies Drug Product Overview
10.16.3 Regeneron Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.16.4 Regeneron Business Overview
10.16.5 Regeneron Recent Developments
10.17 Innovent
10.17.1 Innovent Therapeutic Monoclonal Antibodies Drug Basic Information
10.17.2 Innovent Therapeutic Monoclonal Antibodies Drug Product Overview
10.17.3 Innovent Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.17.4 Innovent Business Overview
10.17.5 Innovent Recent Developments
10.18 Hengrui Medicine
10.18.1 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Basic Information
10.18.2 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Overview
10.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Market Performance
10.18.4 Hengrui Medicine Business Overview
10.18.5 Hengrui Medicine Recent Developments
11 Therapeutic Monoclonal Antibodies Drug Market Forecast by Region
11.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast
11.2 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country
11.2.3 Asia Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region
11.2.4 South America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Therapeutic Monoclonal Antibodies Drug by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Therapeutic Monoclonal Antibodies Drug by Type (2025-2032)
12.1.2 Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Therapeutic Monoclonal Antibodies Drug by Type (2025-2032)
12.2 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Application (2025-2032)
12.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) Forecast by Application
12.2.2 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Therapeutic Monoclonal Antibodies Drug Market Size Comparison by Region (M USD)
Table 5. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Therapeutic Monoclonal Antibodies Drug Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Therapeutic Monoclonal Antibodies Drug Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Monoclonal Antibodies Drug as of 2022)
Table 10. Global Market Therapeutic Monoclonal Antibodies Drug Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Therapeutic Monoclonal Antibodies Drug Sales Sites and Area Served
Table 12. Manufacturers Therapeutic Monoclonal Antibodies Drug Product Type
Table 13. Global Therapeutic Monoclonal Antibodies Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Therapeutic Monoclonal Antibodies Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Therapeutic Monoclonal Antibodies Drug Market Challenges
Table 22. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (K MT)
Table 23. Global Therapeutic Monoclonal Antibodies Drug Market Size by Type (M USD)
Table 24. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Type (2019-2025)
Table 25. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2019-2025)
Table 26. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) by Type (2019-2025)
Table 27. Global Therapeutic Monoclonal Antibodies Drug Market Size Share by Type (2019-2025)
Table 28. Global Therapeutic Monoclonal Antibodies Drug Price (USD/MT) by Type (2019-2025)
Table 29. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Application
Table 30. Global Therapeutic Monoclonal Antibodies Drug Market Size by Application
Table 31. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2019-2025) & (K MT)
Table 32. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2019-2025)
Table 33. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2019-2025) & (M USD)
Table 34. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application (2019-2025)
Table 35. Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2025)
Table 36. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2025) & (K MT)
Table 37. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2019-2025)
Table 38. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2025) & (K MT)
Table 39. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2025) & (K MT)
Table 41. South America Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2025) & (K MT)
Table 43. Global Therapeutic Monoclonal Antibodies Drug Production (K MT) by Region (2019-2025)
Table 44. Global Therapeutic Monoclonal Antibodies Drug Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2019-2025)
Table 46. Global Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. AbbVie Therapeutic Monoclonal Antibodies Drug Basic Information
Table 52. AbbVie Therapeutic Monoclonal Antibodies Drug Product Overview
Table 53. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. AbbVie Business Overview
Table 55. AbbVie Therapeutic Monoclonal Antibodies Drug SWOT Analysis
Table 56. AbbVie Recent Developments
Table 57. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Basic Information
Table 58. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Overview
Table 59. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Johnson and Johnson Business Overview
Table 61. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug SWOT Analysis
Table 62. Johnson and Johnson Recent Developments
Table 63. Novartis Therapeutic Monoclonal Antibodies Drug Basic Information
Table 64. Novartis Therapeutic Monoclonal Antibodies Drug Product Overview
Table 65. Novartis Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Novartis Therapeutic Monoclonal Antibodies Drug SWOT Analysis
Table 67. Novartis Business Overview
Table 68. Novartis Recent Developments
Table 69. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Basic Information
Table 70. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Overview
Table 71. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Gilead Sciences Business Overview
Table 73. Gilead Sciences Recent Developments
Table 74. Roche Therapeutic Monoclonal Antibodies Drug Basic Information
Table 75. Roche Therapeutic Monoclonal Antibodies Drug Product Overview
Table 76. Roche Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Roche Business Overview
Table 78. Roche Recent Developments
Table 79. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Basic Information
Table 80. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Overview
Table 81. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Amgen Therapeutic Monoclonal Antibodies Drug Basic Information
Table 85. Amgen Therapeutic Monoclonal Antibodies Drug Product Overview
Table 86. Amgen Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Amgen Business Overview
Table 88. Amgen Recent Developments
Table 89. AstraZeneca Therapeutic Monoclonal Antibodies Drug Basic Information
Table 90. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Overview
Table 91. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Recent Developments
Table 94. Merck and Co Therapeutic Monoclonal Antibodies Drug Basic Information
Table 95. Merck and Co Therapeutic Monoclonal Antibodies Drug Product Overview
Table 96. Merck and Co Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Merck and Co Business Overview
Table 98. Merck and Co Recent Developments
Table 99. Takeda Therapeutic Monoclonal Antibodies Drug Basic Information
Table 100. Takeda Therapeutic Monoclonal Antibodies Drug Product Overview
Table 101. Takeda Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Takeda Business Overview
Table 103. Takeda Recent Developments
Table 104. Merck KGaA Therapeutic Monoclonal Antibodies Drug Basic Information
Table 105. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Overview
Table 106. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Recent Developments
Table 109. Seagen Therapeutic Monoclonal Antibodies Drug Basic Information
Table 110. Seagen Therapeutic Monoclonal Antibodies Drug Product Overview
Table 111. Seagen Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. Seagen Business Overview
Table 113. Seagen Recent Developments
Table 114. Eli Lilly Therapeutic Monoclonal Antibodies Drug Basic Information
Table 115. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Overview
Table 116. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Eli Lilly Business Overview
Table 118. Eli Lilly Recent Developments
Table 119. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Basic Information
Table 120. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Overview
Table 121. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. Ono Pharmaceutical Business Overview
Table 123. Ono Pharmaceutical Recent Developments
Table 124. Pfizer Therapeutic Monoclonal Antibodies Drug Basic Information
Table 125. Pfizer Therapeutic Monoclonal Antibodies Drug Product Overview
Table 126. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 127. Pfizer Business Overview
Table 128. Pfizer Recent Developments
Table 129. Regeneron Therapeutic Monoclonal Antibodies Drug Basic Information
Table 130. Regeneron Therapeutic Monoclonal Antibodies Drug Product Overview
Table 131. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 132. Regeneron Business Overview
Table 133. Regeneron Recent Developments
Table 134. Innovent Therapeutic Monoclonal Antibodies Drug Basic Information
Table 135. Innovent Therapeutic Monoclonal Antibodies Drug Product Overview
Table 136. Innovent Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 137. Innovent Business Overview
Table 138. Innovent Recent Developments
Table 139. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Basic Information
Table 140. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Overview
Table 141. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 142. Hengrui Medicine Business Overview
Table 143. Hengrui Medicine Recent Developments
Table 144. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region (2025-2032) & (K MT)
Table 145. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region (2025-2032) & (M USD)
Table 146. North America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 147. North America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 148. Europe Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 149. Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 150. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region (2025-2032) & (K MT)
Table 151. Asia Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region (2025-2032) & (M USD)
Table 152. South America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 153. South America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 154. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Consumption Forecast by Country (2025-2032) & (Units)
Table 155. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 156. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Type (2025-2032) & (K MT)
Table 157. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Type (2025-2032) & (M USD)
Table 158. Global Therapeutic Monoclonal Antibodies Drug Price Forecast by Type (2025-2032) & (USD/MT)
Table 159. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) Forecast by Application (2025-2032)
Table 160. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Therapeutic Monoclonal Antibodies Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD), 2019-2032
Figure 5. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) (2019-2032)
Figure 6. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Therapeutic Monoclonal Antibodies Drug Market Size by Country (M USD)
Figure 11. Therapeutic Monoclonal Antibodies Drug Sales Share by Manufacturers in 2023
Figure 12. Global Therapeutic Monoclonal Antibodies Drug Revenue Share by Manufacturers in 2023
Figure 13. Therapeutic Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Therapeutic Monoclonal Antibodies Drug Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Therapeutic Monoclonal Antibodies Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Therapeutic Monoclonal Antibodies Drug Market Share by Type
Figure 18. Sales Market Share of Therapeutic Monoclonal Antibodies Drug by Type (2019-2025)
Figure 19. Sales Market Share of Therapeutic Monoclonal Antibodies Drug by Type in 2023
Figure 20. Market Size Share of Therapeutic Monoclonal Antibodies Drug by Type (2019-2025)
Figure 21. Market Size Market Share of Therapeutic Monoclonal Antibodies Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application
Figure 24. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2019-2025)
Figure 25. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application in 2023
Figure 26. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application (2019-2025)
Figure 27. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application in 2023
Figure 28. Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2025)
Figure 29. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2019-2025)
Figure 30. North America Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023
Figure 32. U.S. Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Therapeutic Monoclonal Antibodies Drug Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Therapeutic Monoclonal Antibodies Drug Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023
Figure 37. Germany Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region in 2023
Figure 44. China Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)
Figure 50. South America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023
Figure 51. Brazil Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2019-2025)
Figure 62. North America Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2025)
Figure 65. China Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Type (2025-2032)
Figure 70. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Application (2025-2032)
Figure 71. Global Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Application (2025-2032)
